Compare GRMN & BDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GRMN | BDX |
|---|---|---|
| Founded | 1990 | 1897 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.4B | 51.5B |
| IPO Year | 2000 | 1995 |
| Metric | GRMN | BDX |
|---|---|---|
| Price | $267.19 | $158.33 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 13 |
| Target Price | ★ $256.40 | $186.00 |
| AVG Volume (30 Days) | 585.5K | ★ 2.2M |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | 1.57% | ★ 2.65% |
| EPS Growth | ★ 17.67 | N/A |
| EPS | ★ 8.59 | 1.34 |
| Revenue | $7,245,519,000.00 | ★ $21,840,000,000.00 |
| Revenue This Year | $12.15 | N/A |
| Revenue Next Year | $8.69 | $3.02 |
| P/E Ratio | ★ $31.11 | $117.88 |
| Revenue Growth | ★ 15.06 | 8.24 |
| 52 Week Low | $178.74 | $152.79 |
| 52 Week High | $273.32 | $213.08 |
| Indicator | GRMN | BDX |
|---|---|---|
| Relative Strength Index (RSI) | 71.06 | 45.46 |
| Support Level | $228.60 | $153.27 |
| Resistance Level | N/A | $159.71 |
| Average True Range (ATR) | 5.46 | 2.92 |
| MACD | 2.14 | 1.20 |
| Stochastic Oscillator | 86.69 | 67.62 |
Garmin produces GPS-enabled hardware and software for five sectors: fitness, outdoors, automotive, aviation, and marine. Garmin has built a strong reputation for durable, high-precision devices through a vertically integrated design and manufacturing approach. The company's product lines include smartwatches, fitness trackers, communication equipment, and a comprehensive suite of systems for marine and aviation navigation. Garmin operates globally, with its business focused primarily on North America and Europe.
Becton Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures prefilled devices, diagnostic instruments, and reagents, as well as flow cytometry and cell-imaging systems. On a 2025 sales basis, following the spinoff, BD Medical Essentials represented 34% of revenue, the Interventional segment 28%, Connected Care 25%, and Biopharma 13%. International revenue accounts for 43% of the company's business.